Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of HL05 versus Xgeva in patients with bone metastases from solid tumors
CTR20223114Phase 3Completed
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HL05, denosumab in bone metastases, sponsored by Hualan Ankang Biotechnology. Started Feb 2023; status: completed.
02
Drugs
HL05denosumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20223114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223114.